Rotavirus, Vaccine and Unanswered Questions: A Perspective from a Least Developed Country
Two rotavirus vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline) have been developed
to neutralize the most common rotavirus serotypes, and are now available in the global market.
These vaccines are primarily aimed at reducing rotavirus gastroenteritis in children in the least
developed countries, where rotavirus mortality rate is believed to be greatest. Thus, the World
Health Organization (WHO) has recommended rotavirus vaccination be included in all national
immunization programs, while the least developed countries have so far not come up with clear
vision and long term strategy on vaccine implementation, and several questions, in addition to this,
Keywords: least developed country; rotavirus; vaccines.
JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.